| Abigail Mclaughlin, | |
|
1401 Atlantic Ave, Atlantic City, NJ 08401-7001 | |
| (609) 345-4000 | |
| Not Available |
| Full Name | Abigail Mclaughlin |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 1401 Atlantic Ave, Atlantic City, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417696105 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LG0600X | Nurse Practitioner - Gerontology | 26NJ01285400 (New Jersey) | Secondary |
| 363LP2300X | Nurse Practitioner - Primary Care | 26NJ01285400 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atlanticare Health Services, Inc. | 7911810916 | 39 |
News Archive
Now that the long-awaited Baucus health overhaul is out, Democratic leaders are pondering how they will collect the votes and support necessary to move a bill through Congress.
Questcor Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has informed Questcor that the FDA will require additional time beyond the current action date of September 11, 2010 to complete its review of Questcor's supplemental new drug application for H.P. Acthar Gel (repository corticotropin injection) in the treatment of infantile spasms.
Researchers from Ben-Gurion University (BGU), together with American and German colleagues, have developed new "molecular tweezers" to combat antibiotic-resistant bacteria. Their recently announced findings were published in Cell Chemical Biology.
Boston Therapeutics, Inc. (BTI), a public company registered with the SEC and a developer of diabetes therapeutics, announced today the completion of a trial in healthy volunteers performed at the University of Sydney on SUGARDOWN, a dietary supplement designed to reduce post-meal elevation of blood glucose.
Today the Alzheimer's Drug Discovery Foundation and the Alzheimer's Society (UK) announced a new partnership that will provide funding for research in Alzheimer's disease and related dementias, with the goal of accelerating critical development programs and bringing new treatments to patients. The partnership intends to fund projects up to $1.5 million each focused on drug repurposing, leveraging existing scientific evidence and research to accelerate the drug development process.
› Verified 9 days ago
| Entity Name | Atlanticare Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215987771 PECOS PAC ID: 7911810916 Enrollment ID: O20040719001204 |
News Archive
Now that the long-awaited Baucus health overhaul is out, Democratic leaders are pondering how they will collect the votes and support necessary to move a bill through Congress.
Questcor Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has informed Questcor that the FDA will require additional time beyond the current action date of September 11, 2010 to complete its review of Questcor's supplemental new drug application for H.P. Acthar Gel (repository corticotropin injection) in the treatment of infantile spasms.
Researchers from Ben-Gurion University (BGU), together with American and German colleagues, have developed new "molecular tweezers" to combat antibiotic-resistant bacteria. Their recently announced findings were published in Cell Chemical Biology.
Boston Therapeutics, Inc. (BTI), a public company registered with the SEC and a developer of diabetes therapeutics, announced today the completion of a trial in healthy volunteers performed at the University of Sydney on SUGARDOWN, a dietary supplement designed to reduce post-meal elevation of blood glucose.
Today the Alzheimer's Drug Discovery Foundation and the Alzheimer's Society (UK) announced a new partnership that will provide funding for research in Alzheimer's disease and related dementias, with the goal of accelerating critical development programs and bringing new treatments to patients. The partnership intends to fund projects up to $1.5 million each focused on drug repurposing, leveraging existing scientific evidence and research to accelerate the drug development process.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Abigail Mclaughlin, 1401 Atlantic Ave, Atlantic City, NJ 08401-7001 Ph: () - | Abigail Mclaughlin, 1401 Atlantic Ave, Atlantic City, NJ 08401-7001 Ph: (609) 345-4000 |
News Archive
Now that the long-awaited Baucus health overhaul is out, Democratic leaders are pondering how they will collect the votes and support necessary to move a bill through Congress.
Questcor Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has informed Questcor that the FDA will require additional time beyond the current action date of September 11, 2010 to complete its review of Questcor's supplemental new drug application for H.P. Acthar Gel (repository corticotropin injection) in the treatment of infantile spasms.
Researchers from Ben-Gurion University (BGU), together with American and German colleagues, have developed new "molecular tweezers" to combat antibiotic-resistant bacteria. Their recently announced findings were published in Cell Chemical Biology.
Boston Therapeutics, Inc. (BTI), a public company registered with the SEC and a developer of diabetes therapeutics, announced today the completion of a trial in healthy volunteers performed at the University of Sydney on SUGARDOWN, a dietary supplement designed to reduce post-meal elevation of blood glucose.
Today the Alzheimer's Drug Discovery Foundation and the Alzheimer's Society (UK) announced a new partnership that will provide funding for research in Alzheimer's disease and related dementias, with the goal of accelerating critical development programs and bringing new treatments to patients. The partnership intends to fund projects up to $1.5 million each focused on drug repurposing, leveraging existing scientific evidence and research to accelerate the drug development process.
› Verified 9 days ago
Mr. Matthew R Soos, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave, Atlantic City, NJ 08401 Phone: 609-572-8600 | |
Helene E Fedele, ACNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2922 Atlantic Ave, 2nd Floor, Atlantic City, NJ 08401 Phone: 609-437-2020 Fax: 609-345-4290 | |
Nediya Griffith, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2009 Bacharach Blvd, Atlantic City, NJ 08401 Phone: 609-344-5714 Fax: 609-575-6033 | |
Marisa B Scibilia, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave., Atlantic City, NJ 08401 Phone: 609-441-8023 | |
Debra Walters-olaru, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 801 Boardwalk, Showboat Wellness Center, Atlantic City, NJ 08401 Phone: 609-343-4003 | |
Kelli L Gramlich, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave, Atlantic City, NJ 08401 Phone: 609-441-8023 | |
Elaina M Nixon, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave, Atlantic City, NJ 08401 Phone: 609-441-8146 |